Madrigal Pharmaceuticals, Inc. financial data

Symbol
MDGL on Nasdaq
Industry
Pharmaceutical Preparations
Location
200 Barr Harbor Drive, Suite 400, West Conshohocken, PA
State of incorporation
Delaware
Fiscal year end
December 31
Former names
SYNTA PHARMACEUTICALS CORP (to 8/1/2016)
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 664 % +138%
Debt-to-equity 43.3 % -71.2%
Return On Equity -95.6 % +66.5%
Return On Assets -66.7 % +41.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.7M shares +17.5%
Common Stock, Shares, Outstanding 19.9M shares +7.67%
Entity Public Float 3.16B USD +221%
Common Stock, Value, Issued 2K USD 0%
Weighted Average Number of Shares Outstanding, Basic 21.4M shares +16.9%
Weighted Average Number of Shares Outstanding, Diluted 21.4M shares +16.9%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Revenue from Contract with Customer, Excluding Assessed Tax 14.6M USD
General and Administrative Expense 108M USD +125%
Operating Income (Loss) -530M USD -60.5%
Net Income (Loss) Attributable to Parent -510M USD -54.8%
Earnings Per Share, Basic -25.5 USD/shares -36.7%
Earnings Per Share, Diluted -25.5 USD/shares -36.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 495M USD +541%
Cash, Cash Equivalents, and Short-term Investments 1.06B USD
Accounts Receivable, after Allowance for Credit Loss, Current 6.9M USD
Inventory, Net 7.07M USD
Assets, Current 1.09B USD +262%
Property, Plant and Equipment, Net 1.7M USD +273%
Operating Lease, Right-of-Use Asset 1.46M USD +254%
Assets 1.1B USD +264%
Accounts Payable, Current 8.99M USD -48.7%
Employee-related Liabilities, Current 21.3M USD
Accrued Liabilities, Current 116M USD +41.4%
Liabilities, Current 125M USD +25.5%
Operating Lease, Liability, Noncurrent 900K USD
Liabilities 243M USD +22%
Accumulated Other Comprehensive Income (Loss), Net of Tax -368K USD -313%
Retained Earnings (Accumulated Deficit) -1.64B USD -45.4%
Stockholders' Equity Attributable to Parent 857M USD +728%
Liabilities and Equity 1.1B USD +264%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -149M USD -77.4%
Net Cash Provided by (Used in) Financing Activities 574M USD +989%
Net Cash Provided by (Used in) Investing Activities 98.1M USD
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 19.9M shares +7.67%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 523M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 500M USD +547%
Deferred Tax Assets, Valuation Allowance 383M USD +41.3%
Deferred Tax Assets, Gross 383M USD +41.4%
Operating Lease, Liability 1.71M USD +185%
Payments to Acquire Property, Plant, and Equipment 357K USD +920%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -511M USD -55%
Lessee, Operating Lease, Liability, to be Paid 1.86M USD +199%
Operating Lease, Liability, Current 557K USD +35.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 478K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 937K USD +50.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure +59.5%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 148K USD +640%
Lessee, Operating Lease, Liability, to be Paid, Year Three 446K USD
Deferred Tax Assets, Operating Loss Carryforwards 122M USD +78%
Preferred Stock, Shares Issued 2.37M shares 0%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Preferred Stock, Shares Outstanding 2.37M shares 0%
Depreciation, Depletion and Amortization 168K USD +35.5%
Deferred Tax Assets, Net of Valuation Allowance 117K USD
Share-based Payment Arrangement, Expense 71.8M USD +86.9%
Interest Expense 15M USD +77.8%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%